Your browser doesn't support javascript.
loading
Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.
Barbhaiya, Medha; Zuily, Stephane; Ahmadzadeh, Yasaman; Amigo, Mary-Carmen; Avcin, Tadej; Bertolaccini, Maria Laura; Branch, D Ware; de Jesus, Guilherme; Devreese, Katrien M J; Frances, Camille; Garcia, David; Guillemin, Francis; Levine, Steven R; Levy, Roger A; Lockshin, Michael D; Ortel, Thomas L; Seshan, Surya V; Tektonidou, Maria; Wahl, Denis; Willis, Rohan; Naden, Ray; Costenbader, Karen; Erkan, Doruk.
Affiliation
  • Barbhaiya M; Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.
  • Zuily S; Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Université de Lorraine, Inserm, DCAC, and CHRU-Nancy, Nancy, France.
  • Ahmadzadeh Y; Hospital for Special Surgery, New York, New York.
  • Amigo MC; ABC Medical Center, Mexico City, Mexico.
  • Avcin T; Children's Hospital, University Medical Center, University of Ljubljana, Ljubljana, Slovenia.
  • Bertolaccini ML; King's College London British Heart Foundation Centre of Excellence, London, UK.
  • Branch DW; University of Utah Health, Salt Lake City.
  • de Jesus G; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Devreese KMJ; Ghent University Hospital, Ghent University, Ghent, Belgium.
  • Frances C; Tenon Hospital, Paris, France.
  • Garcia D; University of Washington, Seattle.
  • Guillemin F; CIC Clinical Epidemiology, APEMAC and CHRU, Inserm, Université de Lorraine, Nancy, France.
  • Levine SR; Downstate Stroke Center, State University of New York Downstate Health Sciences University, Kings County Hospital Center, and Maimonides Medical Center/Jaffe Stroke Center, Brooklyn, New York.
  • Levy RA; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, and GlaxoSmithKline, Upper Providence, Pennsylvania.
  • Lockshin MD; Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.
  • Ortel TL; Duke University Medical Center, Durham, North Carolina.
  • Seshan SV; Weill Cornell Medicine, New York, New York.
  • Tektonidou M; University of Athens, Athens, Greece.
  • Wahl D; Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Université de Lorraine, Inserm, DCAC, and CHRU-Nancy, Nancy, France.
  • Willis R; University of Texas Medical Branch, Galveston.
  • Costenbader K; Brigham and Women's Hospital, Boston, Massachusetts.
  • Erkan D; Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.
Arthritis Care Res (Hoboken) ; 73(10): 1490-1501, 2021 10.
Article in En | MEDLINE | ID: mdl-33253499
ABSTRACT

OBJECTIVE:

An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence- and consensus-based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains.

METHODS:

During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains.

RESULTS:

Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification.

CONCLUSION:

Using data- and consensus-driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real-world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rheumatology / Antiphospholipid Syndrome Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Arthritis Care Res (Hoboken) Journal subject: REUMATOLOGIA Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rheumatology / Antiphospholipid Syndrome Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Arthritis Care Res (Hoboken) Journal subject: REUMATOLOGIA Year: 2021 Document type: Article